SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies touches roof on securing renewal of DSIR R&D recognition for VMRC

05 Jun 2026 Evaluate

Venus Remedies is currently trading at upper limit of Rs. 1637.10, up by 77.95 points or 5.00% from its previous closing of Rs. 1559.15 on the BSE.

The scrip opened at Rs. 1609.65 and has touched a high and low of Rs. 1637.10 and Rs. 1559.15 respectively. So far 22043 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1,637.10 on 05-Jun-2026 and a 52 week low of Rs. 417.65 on 25-Jun-2025.

Last one week high and low of the scrip stood at Rs. 1,637.10 and Rs. 877.75 respectively. The current market cap of the company is Rs. 2188.31 crore.

The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 4.00% and 54.24% respectively.

Venus Remedies has secured the renewal of in-house Research & Development (R&D) recognition from the Department of Scientific and Industrial Research (DSIR), Government of India, for its R&D unit, Venus Medicine Research Centre (VMRC).

DSIR recognition is granted to organisations that operate a dedicated in-house R&D unit with defined research objectives, qualified scientific staff, and separately accounted R&D expenditure. The renewal confirms that VMRC continues to meet these conditions.

The recognition supports VMRC's ongoing work in antimicrobial resistance, including the development of VRP-034, a novel polymyxin 8 formulation that holds USFDA Qualified Infectious Disease Product (QIDP) designation, and the GASAR resistance surveillance study.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.

Venus Remedies Share Price

1801.25 84.80 (4.94%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.25
Dr. Reddys Lab 1273.90
Cipla 1388.80
Zydus Lifesciences 1104.35
Lupin 2292.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: